scholarly journals Rates of longitudinal change in 18 F‐flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease

2021 ◽  
Author(s):  
Jeffrey S. Phillips ◽  
Frederick J. Nitchie ◽  
Fulvio Da Re ◽  
Christopher A. Olm ◽  
Philip A. Cook ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Brain Region ◽  
Longitudinal Change ◽  
Atypical Alzheimer’S Disease

scholarly journals A Non Invasive Biomarkers for Alzheimer’s disease Detection

2019 ◽  
Vol 8 (2S5) ◽  
pp. 1-6
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Brain Region ◽  
Healthcare Costs ◽  
Elderly Population ◽  
Life Quality ◽  
Patient Specific ◽  
Non Invasive ◽  
Over Time

Alzheimer's disease (AD) is one of the most common neurodegenerative diseases occurring in elderly population worldwide, which usually starts slowly and worsens over time. AD is generally diagnosed too late, when irreversible damages have been caused in the patient’s brain region. Present need demands the discovery of diagnostic and prognostic patient specific effective biomarkers to improve patient’s life quality and avoid big healthcare costs. Objective of this survey is to review the non-invasive biomarkers that could be used to predict early onset of AD and delay cognitive impairment.

scholarly journals Reduced longitudinal change in 18 F‐flortaucipir PET is associated with clinical phenotype in atypical Alzheimer’s disease

2021 ◽  
Vol 17 (S1) ◽  
Author(s):  
Jeffrey S Phillips ◽  
Frederick J. Nitchie ◽  
Fulvio Da Re ◽  
Christopher A Olm ◽  
Philip Cook ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Phenotype ◽  
Longitudinal Change ◽  
Atypical Alzheimer’S Disease

scholarly journals The New Therapeutics in Alzheimer's Disease Longitudinal Cohort study (NTAD): study protocol

2021 ◽  
Author(s):  
Juliette Helene Lanskey ◽  
Ece Kocagoncu ◽  
Andrew J Quinn ◽  
Yun-Ju Cheng ◽  
Melek Karadag ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Early Stage ◽  
Cognitive Change ◽  
Longitudinal Change ◽  
Central Research ◽  
Imaging Data ◽  
One Year

Introduction With the pressing need to develop treatments that slow or stop the progression of Alzheimer's disease, new tools are needed to reduce clinical trial duration and validate new targets for human therapeutics. Such tools could be derived from neurophysiological measurements of disease. Methods and Analysis The New Therapeutics in Alzheimer's disease study (NTAD) aims to identify a biomarker set from magneto/electro-encephalographic that is sensitive to disease and progression over one year. The study will recruit 100 people with amyloid-positive mild cognitive impairment or early-stage Alzheimer's disease and 30 healthy controls aged between 50 and 85 years. Repeat measurements of the clinical, cognitive and imaging data (magnetoencephalography, electroencephalography and magnetic resonance imaging) of participants with Alzheimer's disease or mild cognitive impairment will be taken at baseline and at one year. To assess reliability of magneto/electro-encephalographic changes, a subset of 30 participants with mild cognitive impairment or early-stage Alzheimer's disease will undergo repeat magneto/electro-encephalographic two weeks after baseline. Clinical and cognitive assessment will be repeated at 2 years. Linear mixed models of baseline and longitudinal change in neurophysiology are the primary analyses of interest, supported by Bayesian inference. Additional outputs will include relative effect sizes for physiological markers, atrophy and cognitive change and the respective numbers needed to treat each arm of simulated clinical trials of a future disease modifying therapy. Ethics and dissemination The study has received a favourable opinion from the East of England Cambridge Central Research Ethics Committee (REC reference 18/EE/0042). Results will be disseminated through internal reports, peer-reviewed scientific journals, conference presentations, website publication, submission to regulatory authorities and other publications. Data will be made available via the Dementias Platform UK Data Portal on completion of initial analyses by the NTAD study group.

scholarly journals Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e043114
Author(s):  
Chinedu T. Udeh-Momoh ◽  
Tamlyn Watermeyer ◽  
Geraint Price ◽  
Celeste A de Jager Loots ◽  
Natalia Reglinska-Matveyev ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Brain Mri ◽  
Longitudinal Change ◽  
Community Research ◽  
Central Research ◽  
Cognitive Health ◽  
Functional Changes ◽  
Dementia Research

IntroductionThe Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy (CPSS), sponsored by Janssen Pharmaceutical Research & Development LLC, is an Alzheimer’s disease (AD) biomarker enriched observational study that began 3 July 2015 CPSS aims to identify and validate determinants of AD, alongside cognitive, functional and biological changes in older adults with or without detectable evidence of AD pathology at baseline.Methods and analysisCPSS is a dual-site longitudinal cohort (3.5 years) assessed quarterly. Cognitively normal participants (60–85 years) were recruited across Greater London and Edinburgh. Participants are classified as high, medium (amnestic or non-amnestic) or low risk for developing mild cognitive impairment–Alzheimer’s disease based on their Repeatable Battery for the Assessment of Neuropsychological Status performance at screening. Additional AD-related assessments include: a novel cognitive composite, the Global Preclinical Alzheimer’s Cognitive Composite, brain MRI and positron emission tomography and cerebrospinal fluid analysis. Lifestyle, other cognitive and functional data, as well as biosamples (blood, urine, and saliva) are collected. Primarily, study analyses will evaluate longitudinal change in cognitive and functional outcomes. Annual interim analyses for descriptive data occur throughout the course of the study, although inferential statistics are conducted as required.Ethics and disseminationCPSS received ethical approvals from the London—Central Research Ethics Committee (15/LO/0711) and the Administration of Radioactive Substances Advisory Committee (RPC 630/3764/33110) The study is at the forefront of global AD prevention efforts, with frequent and robust sampling of the well-characterised cohort, allowing for detection of incipient pathophysiological, cognitive and functional changes that could inform therapeutic strategies to prevent and/or delay cognitive impairment and dementia. Dissemination of results will target the scientific community, research participants, volunteer community, public, industry, regulatory authorities and policymakers. On study completion, and following a predetermined embargo period, CPSS data are planned to be made accessible for analysis to facilitate further research into the determinants of AD pathology, onset of symptomatology and progression.Trial registration numberThe CHARIOT:PRO SubStudy is registered with clinicaltrials.gov (NCT02114372). Notices of protocol modifications will be made available through this trial registry.

scholarly journals Increasing Inaccuracy of Self-Reported Subjective Cognitive Complaints Over 24 Months in Empirically Derived Subtypes of Mild Cognitive Impairment

2018 ◽  
Vol 24 (8) ◽  
pp. 842-853 ◽  
Author(s):  
Emily C. Edmonds ◽  
Alexandra J. Weigand ◽  
Kelsey R. Thomas ◽  
Joel Eppig ◽  
Lisa Delano-Wood ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Decline ◽  
Analysis Of Covariance ◽  
Longitudinal Change ◽  
Cognitive Complaints ◽  
Discrepancy Scores ◽  
Subjective Cognitive Complaints

AbstractObjectives: Although subjective cognitive complaints (SCC) are an integral component of the diagnostic criteria for mild cognitive impairment (MCI), previous findings indicate they may not accurately reflect cognitive ability. Within the Alzheimer’s Disease Neuroimaging Initiative, we investigated longitudinal change in the discrepancy between self- and informant-reported SCC across empirically derived subtypes of MCI and normal control (NC) participants. Methods: Data were obtained for 353 MCI participants and 122 “robust” NC participants. Participants were classified into three subtypes at baseline via cluster analysis: amnestic MCI, mixed MCI, and cluster-derived normal (CDN), a presumptive false-positive group who performed within normal limits on neuropsychological testing. SCC at baseline and two annual follow-up visits were assessed via the Everyday Cognition Questionnaire (ECog), and discrepancy scores between self- and informant-report were calculated. Analysis of change was conducted using analysis of covariance. Results: The amnestic and mixed MCI subtypes demonstrated increasing ECog discrepancy scores over time. This was driven by an increase in informant-reported SCC, which corresponded to participants’ objective cognitive decline, despite stable self-reported SCC. Increasing unawareness was associated with cerebrospinal fluid Alzheimer’s disease biomarker positivity and progression to Alzheimer’s disease. In contrast, CDN and NC groups over-reported cognitive difficulty and demonstrated normal cognition at all time points. Conclusions: MCI participants’ discrepancy scores indicate progressive underappreciation of their evolving cognitive deficits. Consistent over-reporting in the CDN and NC groups despite normal objective cognition suggests that self-reported SCC do not predict impending cognitive decline. Results demonstrate that self-reported SCC become increasingly misleading as objective cognitive impairment becomes more pronounced. (JINS, 2018, 24, 842–853)

Sign in / Sign up

Export Citation Format

Share Document